Simulations Plus, Inc. - SLP STOCK NEWS

QHP Capital has announced the sale of Pro-ficiency, a provider of tech-enabled training and compliance solutions for clinical trial investigators, to Simulations Plus (Nasdaq: SLP). Pro-ficiency has grown significantly since QHP's initial investment in 2021, completing acquisitions of Fugitive Labs in 2022 and Compass Group Partners in 2023.

Simulations Plus, a leader in modeling and simulation software and services for pharmaceutical safety and efficacy, views this acquisition as a strategic move to expand its market reach and enhance service offerings. Pro-ficiency's CEO, Michael Raymer, expressed enthusiasm about the merger, highlighting the complementary operations and aligned cultures of the two companies. Both teams are aiming to leverage each other's strengths to improve client performance and attract new customers with comprehensive solutions.

Simulations Plus (Nasdaq: SLP) has acquired Pro-ficiency Holdings for $100 million in cash, expanding its capabilities in drug development and commercialization. This acquisition doubles the company's total addressable market (TAM) to $8 billion and is expected to be accretive to fiscal 2025 EPS. The integration of Pro-ficiency’s simulation-enabled solutions enhances Simulations Plus' existing offerings, providing end-to-end services from pre-clinical protocols to product commercialization. The company will host a conference call to discuss the transaction.

Simulations Plus (Nasdaq: SLP), a leader in modeling and simulation solutions across various industries, will participate in the 21st Annual Craig-Hallum Institutional Investor Conference on May 29, 2024, in Minneapolis. CEO Shawn O'Connor will represent the company, engaging in one-on-one and small group meetings. This event features over 130 public companies, offering institutional clients the opportunity to meet with corporate management. Attendance is by invitation only.

Simulations Plus has launched GastroPlus® X (GPX™), marking a significant upgrade in PBPK/PBBM modeling and simulation software. This new platform offers advanced models, refined algorithms, and integrated machine learning, alongside an intuitive interface and streamlined workflows. GPX is designed to enhance productivity through ease-of-use and faster processing. The development involved extensive user testing and feedback, resulting in a flexible platform that supports diverse research needs. Notably, GPX includes unique features like true polypharmacy simulations and flexible deployment options, including cloud integration. Available for licensing now, GPX aims to expand Simulations Plus's global market reach.

Simulations Plus, Inc. (SLP) announces the FDA renewal of DILIsym software licenses, a key tool for predicting drug-induced liver injury risk. The software aids in evaluating potential DILI risk, understanding compound mechanisms, and tailoring dosing strategies for efficacy and safety. Dr. Watkins highlights the importance of predicting safe dosing regimens for effective therapies. The incorporation of quantitative systems pharmacology and toxicology models by the FDA showcases the industry's shift towards advanced evaluation tools.

Simulations Plus (SLP) reports strong financial results for Q2 fiscal 2024, with total revenue of $18.3 million and diluted EPS of $0.20. The company maintains full-year revenue guidance of $66 to $69 million and EPS guidance of $0.66 to $0.68. Revenue increased by 16% compared to Q2 2023, driven by growth in software and services segments. The company's management remains optimistic about future demand and strategic investments.

Simulations Plus, Inc. (Nasdaq: SLP) will announce its second-quarter fiscal 2024 financial results on April 3, 2024, after the market closes. A conference call will be held at 5:00 p.m. Eastern Time on the same day to discuss the results.

Simulations Plus, Inc. (SLP) CEO to host fireside chat at KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum. Live webcast available for replay for 90 days.

Simulations Plus, Inc. (SLP) partners with the University of Bath and other institutions to develop an enhanced dermal PBBM/PBPK model for topical products, funded by the FDA. The collaboration aims to revolutionize drug product performance prediction, expedite regulatory decisions, and benefit patients and the pharmaceutical industry.